Biotech Coverage After the Collapse of Trumpcare: Today’s Research Reports on Cara Therapeutics and Corbus Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 28, 2017 /
Biotech stocks started the day unsurprisingly on a high today (Monday 28), with the collapse of Trumpcare bringing with it certainty in the market. The best performing ETF; the SPDR Health Care Sector saw a 0.27% rise, with 47 of the 60 equity components quickly catching up.

RDI Initiates
Coverage:

Cara Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CARA

Corbus
Pharmaceuticals Holdings Inc. https://ub.rdinvesting.com/news/?ticker=CRBP

Cara Therapeutics’ share price increased by 0.42% during today’s trading session and is currently trading at $16.76. Things are looking good for the biotech company, with its market capitalization currently standing at $457.6 million. In the last fiscal year, the company experienced one of the most dramatic comebacks in its history, to record a $9 million profit last year.

The share price, however, has been on an upward trend rising from an all-year low of $4.35 and an all-time high of 19.44% per share. Investors are currently holding 423.7 million worth of shares, with an average of 1 million being traded daily. Today’s session saw trading almost break the 2 million mark, to trade at 1.7 million.

It is one of the most consistent stock prices in the industry, and now would be a great time to consider including it in your portfolio.

Access RDI’s Cara Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CARA

The premarket trade on Monday saw Corbus Pharmaceuticals’ shares close the day 5.49% higher than the previous day’s results. The stock price saw its stock price increase by an impressive 114% since 2014 when the company first traded in the stock market.

The trial of Resunab, for the treatment of diffuse cutaneous systemic sclerosis completed the second phase of its trial late last week. The SPDR S&P Pharmaceuticals ETF dipped 19% and the S&P 500 SPX soared 5.9% during today’s trading session.

The company has recently announced its intentions to enter the next phase of developing Resunab, a treatment drug for systematic connective tissue disease.

Access RDI’s Corbus Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=CRBP

Our Actionable Research on Cara Therapeutics Inc. (NASDAQ: CARA) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458323